Grant: Engage Grants Program
Dalhousie University
$25,000.00
Application of Statistical Methods to Analyze a Simulated Breath Sample Dataset to Determine Disease Status
FY 2016-17
Summary
Picomole, based in Moncton NB, has developed an apparatus that proposes to offer non-invasive, low cost andearly detection of lung cancer. Picomole has shown that patients with lung cancer exhale specific compoundswith a signature in the mid-infrared (mid-IR). Their diagnostic device is based on absorption measurements ofthese compounds using Continuous Wave Cavity Ring-Down Spectroscopy (CRDS).Picomole has developed preliminary Bayesian fitting algorithms for determining the composition of breathsamples using publicly available data. The supporting theory is based on well-known inverse methods but hasnot yet been rigorously evaluated. It has shown promise in a limited number of breath samples but largersample sizes and significant algorithmic innovations will be essential. Dr. Mills Flemming's expertise inworking with measurement error will be extremely useful here as will her interest in examining the influence ofprior specifications in Bayesian frameworks. Once the fitting algorithms have been refined and tested, astatistical model will be built that can be applied to real human breath sample data for the purpose ofestimating disease state. That is, the model will infer the presence or absence of disease based onconcentrations of breath metabolites associated with lung cancer. One of the challenges here will be to allowfor more compounds in the model that there are spectral lines. It is believed that a stepwise fitting algorithmusing the Akaike Information Criterion may be useful.Over the past number of years, Picomole has successfully developed technologies to collect data on humanbreath but has not been able to validate their models for these data or propose new more effective ones.Picomole physicists, together with Dr. Mills Flemming will take these next steps forward toward developing acommercially viable product for the Company. Early detection of pulmonary diseases will be a game changerin cancer therapy by eliminating time-consuming invasive surgery and producing a substantial increase in thesurvival rate of lung cancer patients. The success of this project will further strengthen the position of Canada
Program
Engage Grants Program
Recipient
Location
Nova Scotia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
505968-2016
Name nom
Flemming, Joanna
Department département
Mathematics and Statistics
Organization id
79
Institution établissement
Dalhousie University
Province en
Nova Scotia
Province fr
Nouvelle-Écosse
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2016
Competition year année de concours
2016
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1551
Committee name en
Atlantic Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Atlantique
Area of application code
518
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Medical equipment and apparatus
Area of application fr
Appareils et instruments médicaux
Research subject code
3004
Research subject group en
Statistics and probability
Research subject group fr
Statistique et probabilité
Research subject en
Applied statistics
Research subject fr
Statistique appliquée
Partie
1
Nb partie
1
Application title
Application of Statistical Methods to Analyze a Simulated Breath Sample Dataset to Determine Disease Status
Keyword
NSERC
Application summary
Picomole, based in Moncton NB, has developed an apparatus that proposes to offer non-invasive, low cost andearly detection of lung cancer. Picomole has shown that patients with lung cancer exhale specific compoundswith a signature in the mid-infrared (mid-IR). Their diagnostic device is based on absorption measurements ofthese compounds using Continuous Wave Cavity Ring-Down Spectroscopy (CRDS).Picomole has developed preliminary Bayesian fitting algorithms for determining the composition of breathsamples using publicly available data. The supporting theory is based on well-known inverse methods but hasnot yet been rigorously evaluated. It has shown promise in a limited number of breath samples but largersample sizes and significant algorithmic innovations will be essential. Dr. Mills Flemming's expertise inworking with measurement error will be extremely useful here as will her interest in examining the influence ofprior specifications in Bayesian frameworks. Once the fitting algorithms have been refined and tested, astatistical model will be built that can be applied to real human breath sample data for the purpose ofestimating disease state. That is, the model will infer the presence or absence of disease based onconcentrations of breath metabolites associated with lung cancer. One of the challenges here will be to allowfor more compounds in the model that there are spectral lines. It is believed that a stepwise fitting algorithmusing the Akaike Information Criterion may be useful.Over the past number of years, Picomole has successfully developed technologies to collect data on humanbreath but has not been able to validate their models for these data or propose new more effective ones.Picomole physicists, together with Dr. Mills Flemming will take these next steps forward toward developing acommercially viable product for the Company. Early detection of pulmonary diseases will be a game changerin cancer therapy by eliminating time-consuming invasive surgery and producing a substantial increase in thesurvival rate of lung cancer patients. The success of this project will further strengthen the position of Canada